Objective: To investigate whether inhibition of cyclooxygenase-2, a critical component of the inflammatory pathway, is neuroprotective in a neonatal rat model of cerebral hypoxia-ischemia. The development of brain inflammation largely contributes to neonatal brain injury that may lead to a lifetime of neurologic deficits.
A hypoxic-ischemic insult to neonates results not only in brain damage but is also associated with increased mortality and somatic growth retardation (1, 2) . There is no effective treatment for neonatal hypoxia-ischemia (HI). Long-term effects of HI for the survivors may include motor disability, cognitive dysfunction, and problems in learning and behavior (3) . The inflammatory response is particularly detrimental in the immature brain, serving a key component in the progression of neonatal encephalopathy (4) .
Cyclooxygenase-2 (COX-2), the inducible form of the enzyme and a key mediator of inflammation, is critical in different forms of brain injury, such as excitotoxic brain injury, cerebral ischemia, traumatic brain injury, and neurodegenerative disorders (5) . Cerebrospinal fluid concentrations of prostaglandins (PGE), such as PGE 2 and PGI 2 , which are downstream effectors of COX-2 enzyme, have been reported to be significantly higher in children with perinatal hypoxia (6) . Furthermore, pharmacologic inhibition of COX-2 has been shown to be beneficial in brain and spinal cord-related injuries in adults (7, 8) . To date, no study has examined the effects of COX-2 inhibition against neonatal HI-induced brain injury.
Accordingly, we hypothesized that inhibition of COX-2-induced inflammation will reduce brain injury plus improve neurologic outcomes and somatic and systemic organ growth post HI in neonates. We examined the lasting effects of COX-2 inhibition, using two different doses of a selective COX-2 inhibitor, NS398, in a well-established neonatal HI model in rats. We also confirmed the presence of COX-2 in neu-ronal cells and used the proinflammatory cytokine, interleukin (IL)-6, as an end point for inflammation.
MATERIALS AND METHODS
Animal Groups and Operative Procedure. This study was in accordance with the National Institutes of Health guidelines for the treatment of animals and was approved by the Institutional Animal Care and Use Committee at Loma Linda University. Timed pregnant Sprague-Dawley rats were housed with food and water available ad libitum. Postnatal day 10 pups were assigned randomly to the following groups: sham, HI (Vehicle), HI ϩ 10 mg/kg NS398 (NS-10), or HI ϩ 30 mg/kg NS398 . Each litter consisted of all groups. Pups were placed on a surgical table maintained at 37°C and anesthetized by inhalation with isoflurane (3% in mixed air and oxygen). HI groups had the right common carotid artery permanently ligated. After 1.5 hrs of recovery, pups were placed in a glass jar (submerged in a water bath maintained at 37°C) perfused with 8% oxygen for 2 hrs. Rats were euthanized under general anesthesia (ketamine, 80 mg/kg/xylazine, 10 mg/kg) then decipitated at 72 hrs, 2 wks and 6 wks post HI.
Treatment Method. Some pups were treated intraperitoneally with a COX-2 inhibitor (NS398) at either 10 mg/kg or 30 mg/kg dosage (Cayman Chemical, Ann Arbor, MI) diluted in 10% dimethylsulfoxide and saline. Treatment consisted of six injections (1 hr, 6 hrs, 24 hrs, 36 hrs, 48 hrs, and 60 hrs) after hypoxia. Vehicle pups followed same injection regimen and methodology, but they were administered 10% dimethylsulfoxide in saline.
Evaluation of Brain Damage. Hemispheric weight loss has been used as the primary variable to estimate brain damage in this animal model (9) . At 2 wks and 6 wks, the brain was removed, without prior perfusion, and the hemispheres were separated by a midline incision and weighed on a high-precision balance (sensitivity, Ϯ0.001 g).
Measurement of Organ Weight. After removal of brain, the spleen and heart were isolated and detached from surrounding tissue and vessels and weighed at the 6-wk interval.
Assessment of Neurobehavioral Deficits. Rats were tested at 6 wks and scored accordingly: 0 for immediate and correct placement; 1 for delayed and/or incomplete placement; 2 for no placement. Scores corresponded to raw values: 0 ϭ raw value of 100; 1 ϭ raw value of 50; 2 ϭ raw value of 0. Methodology was as previously described (10) for the first six tests:
1. Postural Reflex: Assessed upper body posture and symmetry in forelimb extension (11) . Rat was held by tail and lowered to 10 cm above (12) . Rat was placed in the stem (40 cm ϫ10 cm) of maze and allowed to explore until an arm (46 cm ϫ 10 cm) of maze was chosen. The sequence (ten trials) of left and right arm choices was expressed as rate of spontaneous alternation (0% ϭ no alternation; 100% ϭ alternation at each trial). 8. Foot-Fault: Assessed placement dysfunction of forepaws and motor coordination, and is reliable in differentiating between ischemic and normal rats (11, 13) . Rat was placed onto an elevated wire grid floor (20 cm ϫ 40 cm) for 2 mins. Foot-faults were when a complete paw fell through openings.
Immunohistochemistry with Diaminobenzidin Staining. Animals (n ϭ 5/group) were perfused with 0.1 M of phosphate-buffered saline (PBS) and fixed with 10% paraformaldehyde (formalin) diluted in PBS, via transcardiac approach 72 hrs post insult. The sectioned brain volume (5 mm) encompassed the dorsal hippocampus. Every fifth section of the tissue block was collected, and from this set, six random, nonadjacent sections were stained and then observed. Special care was taken to analyze sections from the same levels of sectioning in different animals. Antigen retrieval was done on slices (10 m) by microwave irradiation in 0.1 M sodium citrate (pH ϭ 6) for 10 mins. Diaminobenzidin staining method (ABC Staining Kit, Santa Cruz Biotech, Santa Cruz, CA) was implemented (14) for detection of COX-2 expression in the ipsilateral cortex and CA1 region of hippocampus. Antibodies included goat anti-COX-2 (1:100) and donkey antigoat secondary antibody (1:200). All antibodies were obtained from Santa Cruz Biotech, unless otherwise stated. Controls for nonspecific immunohistochemical stain-ing were done with omission of the primary antibodies.
Western Blotting of COX-2. Animals (n ϭ 5/group) were perfused (0.1 M PBS) at 72 hrs post HI. Ipsilateral hemisphere was isolated, then snap-frozen, and kept at Ϫ80°C until analysis. Samples in (300 mg/mL) extraction buffer (50 mM Tris-HCl buffer [pH 7.4] with 150 mM NaCl, 1% Nomide P40, 0.1% sodium dodecyl sulfate, 0.1% deoxycholic acid, and 1% phenylmethylsulphonyl fluoride) and 1% protease inhibitor were homogenized with a tissue homogenizer for a total of 60 secs (20 ϫ 3 sec pulses). The homogenate was centrifuged (15,000 g for 20 mins), the supernatant of the extract was collected, and the concentration of the protein samples was determined by Bradford assay (BioRad, Hercules, CA). All procedures were performed at 4°C. 40 g sample of extracted protein with 2ϫ loading buffer (62.5 mM Tris-HCl [pH 6.8], 2% sodium dodecyl sulfate, 25% glycerol, 0.01% Bromophenol Blue, and 5% ␤-mercaptoethanol) were subjected to electrophoresis on 10% polyacrylamide sodium dodecyl sulfate gel (BioRad). Procedures were performed as previously de-
Long-term effects of NS398 on body weight. Postnatal day 10 rats were induced with a hypoxic-ischemic (HI) event: ligation of right common carotid artery and 2 hrs hypoxia (8% oxygen) (Vehicle), then treated with six intraperitoneal injections (1 hr, 6 hrs, 24 hrs, 36 hrs, 48 hrs, and 60 hrs after hypoxia) of a selective cyclooxygenase-2 (COX-2) inhibitor at either 10 mg/kg (NS-10) or 30 mg/kg (NS-30) dosage. Sham animals had same anesthesia and surgical procedure, except that the common carotid artery was not ligated. A) Vehicle animals had a significantly lower mean body weight at 2 wks, 3 wks, and 6 wks, compared with sham (*p Ͻ .05). NS-30 had long-term lasting effects as it maintained body weight compared with vehicle 6 wks after HI (#p Ͻ .05). Only mean body weights of animals kept through the 6-wk time point are represented (n ϭ 9/group). B) Differences in fur texture and appearance were detected as early as 2 wks between treated (T) and untreated rats (U). C) Close-up picture demonstrating the somatic differences between treated and untreated rats at 2 wks. scribed (15) . Primary antibodies were goat anti-COX-2 and rabbit anti-␤-actin. Incubation with donkey antigoat and donkey antirabbit secondary antibodies was done, respectively. Bands were detected by chemiluminescent kit (Amersham Bioscience, Piscataway, NJ) on radiograph film (Kodak, Rochester, NY). Optical density was determined, using NIH Image J software and expressed relative to ␤-actin, then to sham group.
Triple Fluorescent Labeling. Cerebral tissue was perfused (0.1 M PBS), fixed (10% formalin), and sectioned (5-mm volume) at 72 hrs for use in triple-fluorescent labeling. Primary antibodies were goat anti-COX-2 (1:50), rabbit anti-IL-6 (1:50) with mouse anti-NeuN (1:100; Millipore Corp., Billerica, MA). Tissue slices (10 m) were blocked with 5% donkey serum in PBS at room temperature for 2 hrs. Slices were incubated overnight at 4°C, followed with respective donkey secondary antibodies conjugated with fluorescent dyes for 2 hrs at room temperature in the dark (16) . Between incubations, three washes of 5 mins were performed at room temperature with 0.01 M PBS (pH 7.4). Controls for nonspecific immunofluorescence staining were done with omission of the primary antibodies. To test for tissue autofluorescence, some sections were processed without the secondary antibodies. The ipsilateral cortex and CA1 region of hippocampus (n ϭ 5/group) were analyzed, using a fluorescent microscope with digital camera (OLYMPUS BX51, Melville, NY).
Inflammatory Cell Infiltration. Animals (n ϭ 5/group) were perfused (0.1 M PBS) at 72 hrs post HI. Ipsilateral hemisphere was isolated, then snap-frozen, and kept at Ϫ80°C until analysis of IL-6 concentration by enzyme-linked immunosorbent assay technique (Invitrogen Corp., Carlsbad, CA) and expressed as picogram per milligram protein. Samples in (300 mg/mL) extraction buffer (50 mM Tris-HCl buffer [pH 7.4] with 0.6 M NaCl, 0.2% Triton X-100, 10 L aprotinin, 1 g/mL leupeptin, and 1 mM phenylmethylsulphonyl fluoride) and 1% protease inhibitor were homogenized, the supernatant of the extract was collected, and the protein samples were assayed in duplicate. Cerebral tissue was perfused (0.1 M PBS), fixed (10% formalin), and sectioned (5-mm volume) for detection of inflammatory cell infiltration into ipsilateral cortex (n ϭ 5/group). Rabbit anti-Iba1 (1:100; Wako Chemicals, Richmond, VA), mouse anti-CD68 (1:100; Millipore Corp.), or goat antimyeloperoxidase (1:100) primary antibodies (Abcam, Cambridge, MA) were added to sections (10 m). Incubation methodology was same as in triple-fluorescent labeling. An estimation of the amount of positive cells were defined as being low (Ͻ10 positive cells/per high-power visual field) or high (Ͼ10 positive cells/per high-power visual field). As with all staining, differences in levels of infiltrating cell markers were noted between groups by an experimenter blinded to the treatment group of each section/slide observed.
Data Analysis. Data were expressed as mean Ϯ SEM. One-way analysis of variance and Tukey test were used to determine significance in differences between means. Neurologic scores were analyzed, using Means of Dunn Method (except T-Maze and Foot-Fault tests); mortality rates using chi-square test; and assays using Dunnett's post hoc test with vehicle designated as control. Significance was accepted at p Ͻ .05.
RESULTS

NS398 Protects Against HI-related
Lethality. Treatment with NS398 com- pletely abolished the mortality evidenced in the untreated group (0% vs. 28.12%). Although nine vehicle pups died within the first 72 hrs after hypoxia, none of the NS398-treated pups died at any time during the experiment, indicating that survival was specifically related to COX-2 inhibition. No sham-operated pups died.
Cyclooxygenase-2 Blockade Maintains Body Weight After HI. Growth retardation is evident in both patients and experimental studies as a result of HI (2, 17) . Accordingly, somatic growth retardation was apparent in vehicle rats at 2 wks, 3 wks, and 6 wks ( Fig. 1A) compared with sham. NS-30 significantly improved body weight at the 6-wk time point. Drastic differences in fur texture and appearance were detected as early as 2 wks between treated and untreated rats ( Fig. 1B and C) .
NS398 Provides Neuroprotection by Maintaining Brain Weight at Two Time Intervals. Hemispheric weight loss is an established estimate of brain damage in this animal model (9) . Severe brain atrophy, marked by a reduction in right-toleft hemispheric weight ratio, was seen in vehicle rats at 2 wks and 6 wks post HI ( Fig. 2A and B) . Blockade of COX-2 protected rats at both time points.
NS398 Prevents HI-related Systemic Organ Atrophy. A reduction in spleen size post middle cerebral artery occlusion model of stroke (18) is correlated with the extent of brain damage (19) . Our experiments supported this observation in the HI neonatal model, with vehicle having a reduced spleen/body weight ratio ( Fig. 2A and C) . Treatment groups demonstrated a trend toward maintaining spleen weight; however, no statistical significance was reached. Heart to body weight ratio decreased in vehicle pups and was attenuated by NS-10 ( Fig. 2A and  C) . Although NS-30 demonstrated a trend toward maintaining heart weight, no significance was reached.
NS398 Prevents Neurobehavior Deficits. Motor, cognitive, and behavioral deficits can be a consequence of perinatal stroke and may last a lifetime (20) . Numbers in parentheses denote mean raw score. Sham demonstrated a successful performance (91.67) in postural reflex test (Fig.  3A) ; treatment (78.57) significantly improved the gross asymmetry in posture and extension of forelimbs seen in vehicle rats (8.33 In T-maze, untreated animals showed a significant decline in memory (reduced % alternations) that was improved by NS-10 and more so by NS-30 (Fig. 3B ). Treatment also significantly at-tenuated the increased number of footfaults in brain injured rats (Fig. 3C) .
NS398 Effectively Reduces Cyclooxygenase-2 Expression. Positive staining for COX-2 was detected by diaminobenzidin stain (Fig. 4A) . The negative control showed no positive staining, indicating that the primary antibody, and not nonspecific immunohistochemical staining, was responsible for the positive signal. NS-30 qualitatively reduced post-HI COX-2 expression in both examined regions of the brain. Higher magnification confirmed COX-2 localization in the cytoplasm of the cell. Western blotting of COX-2 quantitatively supported significant differences between treated and vehicle groups (Fig. 4B) .
NS398 Reduces Cytokine Expression in the Brain. In the hippocampus and cerebral cortex, there was strong neuronal signal for COX-2 and IL-6 in vehicle ( Fig. 5A and B ) . The opposite was seen in NS-30: marked suppression of immunoreactive COX-2 and IL-6, whereas fluorescence was strong for neurons.
COX-2 Inhibition Reduces Inflammatory Infiltration. IL-6 protein level was significantly increased in vehicle and substantially reduced by NS-30 (Fig.  6A ). Single immunofluorescent labeling demonstrated a qualitative increase in expression of microglia (Iba1), macrophages (CD68), and neutrophils (myeloperoxidase) after HI (Fig. 6) ; COX-2 blockade reduced expression of these cell types.
DISCUSSION
In the present study, we tested whether multiple treatments of low-dose or high-dose COX-2 inhibitor, over the first few days after brain insult, can reduce the neurodevelopmental and/or somatic consequences of the injury. We showed for the first time that COX-2 inhibition limited morphologic damage, improved long-term functional deficits, reversed somatic growth retardation, and lowered mortality rates after a hypoxicischemic injury.
NS398 is a well known selective COX-2 inhibitor shown to have neuroprotective effects in adult rat central nervous system injury models (7, 8) . The dosage and treatment frequency (bid) of NS398 was adopted from cerebral ischemia studies in adult rats (7, 21) ; however, the high dose used in this study is slightly higher but comparable to that used in adult rat models (10 -20 mg/kg). Both NS-10 and NS-30 decreased brain damage, as as-sessed by brain weight, at both 2 wks and 6 wks after brain injury. Trends suggested an improvement in spleen weight after NS398 treatment, and significant improvement in heart weight. Similarly, NS-30 consistently improved neurologic deficits 6 wks after insult. This was an important finding, considering past therapeutic modalities in neonatology have resulted in unforeseen side effects (22, 23) . The partial protective effects of NS-10 may be due to the developmental physiologic status of the neonates. Some clinical studies have shown that currently used COX-2 inhibitors, such as celecoxib, are rapidly cleared (twice as fast) in children as compared to adults (24) . Thus, the pharmacokinetics of NS398 needs to be determined in neonatal experimental models. High dose of NS398 also showed an improvement in body weight and other somatic characteristics, such as fur growth and quality. Clinical and experimental studies have shown that neonatal HI not only caused brain damage and neurologic deficits but also decreased somatic growth (2) . The exact mechanism of how COX-2 inhibition affects somatic growth after neonatal HI remains to be determined.
The anti-inflammatory properties of COX-2 inhibition attenuated brain injury after neonatal HI. Overexpression of IL-6 in premature neonates is associated with severe cerebral injury (25) . Studies have shown an IL-6-mediated activation of microglia around site of brain lesion, and a marked reduction of these effects in IL-6 deficient mice (26) . IL-6 is also associated with increased mortality, and is an inde-pendent predictor of neurologic deterioration after ischemic stroke (27, 28) . Inhibition of COX-2 significantly reduced the expression of IL-6, as well as showed a marked reduction in infiltration of inflammatory cells, such as macrophages and neutrophils and decreased activation of microglia in the affected brain tissue. Thus, the neuroprotective effects and increase in survivability demonstrated by COX-2 inhibition may be mediated by a reduction in IL-6 and the subsequent inflammatory response.
Recently, selective COX-2 inhibitors have come under progressively intense scrutiny due to an increased occurrence of cardiovascular events among general populations treated with COX-2 inhibitors. But, the evidence-at-large remains contradictory and a host of studies both affirm and refute the putative cardiovas-cular harms of COX-2 inhibitors, as reviewed by Salinas et al (29) . Furthermore, the underlying disease process and the type of cells involved may be pertinent factors in the overall effect produced by inhibition of COX-2 (29, 30) . These selective inhibitors were commonly prescribed as a chronic regimen for patients with inflammatory arthritis and may thus produce entirely different effects when administered as acute regimens. Until more definitive evidence is available, strong judgments about the harm/benefit ratio of COX-2 inhibitors should be withheld, as these may preempt valuable research into untapped benefits for the general population. As demonstrated in this study, selective inhibition of COX-2 may be effective at protecting the injured neonatal brain and may be a promising therapeutic option as acute treatment after stroke with lasting beneficial effects.
CONCLUSIONS
These results suggest that inhibition of COX-2 may provide major benefits for brain and systemic organ integrity, neurobehavioral deficits, and survival after neonatal HI. Collectively, these data provide a foundation for an investigation of COX-2 inhibitors as treatment for neonatal encephalopathy in the clinical setting. 
